Free tool
FAERS Monitor: Norvasc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019787 or its brand name (Norvasc, Amlodipine Besylate). Reports on generic versions are filed under their own applications.
Reports
147,838
Serious
101,630
69% of reports
Hospitalization
54,341
Death reported
13,282
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue9,860
- nausea8,456
- diarrhoea8,041
- dyspnoea8,012
- drug ineffective7,201
- pain6,914
- dizziness6,652
- headache6,590
- asthenia5,824
- pneumonia5,482
- fall5,476
- off label use5,428
- vomiting5,427
- hypertension5,232
- death4,914
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,379 |
| 2005 | 3,869 |
| 2006 | 4,019 |
| 2007 | 3,206 |
| 2008 | 3,180 |
| 2009 | 3,982 |
| 2010 | 5,808 |
| 2011 | 6,230 |
| 2012 | 6,673 |
| 2013 | 4,898 |
| 2014 | 6,580 |
| 2015 | 7,687 |
| 2016 | 8,465 |
| 2017 | 7,500 |
| 2018 | 7,955 |
| 2019 | 7,850 |
| 2020 | 7,320 |
| 2021 | 7,565 |
| 2022 | 9,886 |
| 2023 | 8,342 |
| 2024 | 8,301 |
| 2025 | 8,803 |
| 2026 | 6,327 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,906,321 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertensionSignal | 5,232 | 3.6 | 3.5 | 9,573 |
| pneumoniaSignal | 5,482 | 2.4 | 2.4 | 4,619 |
| fallSignal | 5,476 | 2.4 | 2.3 | 4,302 |
| astheniaSignal | 5,824 | 2.2 | 2.2 | 3,925 |
| dyspnoeaSignal | 8,012 | 2.0 | 2.0 | 4,229 |
| dizziness | 6,652 | 1.9 | 1.9 | 2,912 |
| fatigue | 9,860 | 1.8 | 1.8 | 3,678 |
| diarrhoea | 8,041 | 1.8 | 1.7 | 2,810 |
| vomiting | 5,427 | 1.6 | 1.6 | 1,403 |
| pain | 6,914 | 1.6 | 1.6 | 1,619 |
| nausea | 8,456 | 1.5 | 1.5 | 1,574 |
| headache | 6,590 | 1.5 | 1.5 | 1,122 |
| off label use | 5,428 | 0.9 | 0.9 | 90 |
| death | 4,914 | 0.8 | 0.8 | 226 |
| drug ineffective | 7,201 | 0.8 | 0.8 | 493 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.